



CLAIMS


1. A compound of Formula I, IA, IB, II, IIA, IIB, III, IIIA, or IIIB:



I,



IA,



IB,



II,


IIA,


IIB,


III,



IIIA,




or IIIB,

or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1 wherein the compound is:



I,



IA or



IB


or a pharmaceutically acceptable salt thereof.


3. The compound of claim 2, wherein the compound is a compound of Formula IA, or a pharmaceutically acceptable salt thereof.


4. The compound of claim 3, wherein the compound has at least 95% ee, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 3, wherein the compound has at least 99% ee, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 wherein the compound is:


II,


IIA or


IIB


or a pharmaceutically acceptable salt thereof.


7. The compound of claim 6, wherein the compound is a compound of Formula IIA, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7, wherein the compound has at least 95% ee, or a pharmaceutically acceptable salt thereof.


9. The compound of claim 7, wherein the compound has at least 99% ee, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 wherein the compound is:


III,



IIIA or



IIIB

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10, wherein the compound is a compound of Formula IIIA, or a pharmaceutically acceptable salt thereof.
12. The compound of claim 11, wherein the compound has at least 95% ee, or a pharmaceutically acceptable salt thereof.
13. The compound of claim 11, wherein the compound has at least 99% ee, or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
15. A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a condition selected from the group consisting of acute neurological and psychiatric disorders; stroke; cerebral ischemia; spinal cord trauma; cognitive impairment; head trauma; perinatal hypoxia; cardiac arrest; hypoglycemic neuronal damage; dementia; Alzheimer's disease; Huntington's Chorea; amyotrophic lateral sclerosis; ocular damage; retinopathy; cognitive disorders; idiopathic and drug-induced Parkinson's disease; muscular spasms and disorders associated with muscular spasticity including tremors; epilepsy; convulsions; migraine; urinary incontinence; substance tolerance; substance withdrawal; psychosis; schizophrenia; negative


symptoms associated with schizophrenia; autism; bipolar disorder; depression; cognitive impairment associated with depression; cognitive impairment associated with cancer therapy; anxiety; mood disorders; inflammatory disorders; sepsis; cirrhosis; cancer and/or tumors associated with immune response escape; trigeminal neuralgia; hearing loss; tinnitus; macular degeneration of the eye; emesis; brain edema; pain; tardive dyskinesia; sleep disorders; attention deficit/hyperactivity disorder; attention deficit disorder; disorders that comprise as a symptom of deficiency in attention and/or cognition; and conduct disorder.

16. Use of a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of a condition selected from the group consisting of acute neurological and psychiatric disorders; stroke; cerebral ischemia; spinal cord trauma; cognitive impairment; head trauma; perinatal hypoxia; cardiac arrest; hypoglycemic neuronal damage; dementia; Alzheimer's disease; Huntington's Chorea; amyotrophic lateral sclerosis; ocular damage; retinopathy; cognitive disorders; idiopathic and drug-induced Parkinson's disease; muscular spasms and disorders associated with muscular spasticity including tremors; epilepsy; convulsions; migraine; urinary incontinence; substance tolerance; substance withdrawal; psychosis; schizophrenia; negative symptoms associated with schizophrenia; autism; bipolar disorder; depression; cognitive impairment associated with depression; cognitive impairment associated with cancer therapy; anxiety; mood disorders; inflammatory disorders; sepsis; cirrhosis; cancer and/or tumors associated with immune response escape; trigeminal neuralgia; hearing loss; tinnitus; macular degeneration of the eye; emesis; brain edema; pain; tardive dyskinesia; sleep disorders; attention deficit/hyperactivity disorder; attention deficit disorder; disorders that comprise as a symptom of deficiency in attention and/or cognition; and conduct disorder.

CLAIMS


1. A compound of Formula I, IA, IB, IIB, III, IIIA, or IIIB:

I




,

IA




;

IB




,

IIB




,

III




,

IIIA



, or


IIIB




or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein the compound is a compound of Formula I, IA, or IB:

I




IA



or


IB



or a pharmaceutically acceptable salt thereof.

3. A compound of Formula IA:

IA




or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3, wherein the compound has at least 95% ee, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 3, wherein the compound has at least 99% ee, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 wherein the compound is a compound of Formula IIB:


IIB



or a pharmaceutically acceptable salt thereof.

7. A compound of Formula IIA

IIA




wherein the compound has at least 95% ee, or a pharmaceutically acceptable salt thereof.


8. The compound of claim 7, wherein the compound has at least 99% ee, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 wherein the compound is a compound of Formula III, IIIA, or IIIB:

III




IIIA



or

IIIB



or a pharmaceutically acceptable salt thereof.

10. The compound of claim 9, wherein the compound is a compound of Formula IIIA, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10, wherein the compound has at least 95% ee, or a pharmaceutically acceptable salt thereof.

12. The compound of claim 10, wherein the compound has at least 99% ee, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a compound of claim 2, or a pharmaceutically

acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a compound of claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a compound of claim 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.